SLC7A5 antibody - N-terminal region (ARP63651_P050)
- Known as:
- SLC7A5 (anti-) - N-terminal region (ARP63651_P050)
- Catalog number:
- arp63651_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- SLC7A5 antibody - N-terminal region (ARP63651_P050)
Related genes to: SLC7A5 antibody - N-terminal region (ARP63651_P050)
- Gene:
- SLC7A5 NIH gene
- Name:
- solute carrier family 7 member 5
- Previous symbol:
- -
- Synonyms:
- LAT1, E16, D16S469E, MPE16, CD98
- Chromosome:
- 16q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-01-28
- Date modifiied:
- 2016-10-05
Related products to: SLC7A5 antibody - N-terminal region (ARP63651_P050)
Related articles to: SLC7A5 antibody - N-terminal region (ARP63651_P050)
- To elucidate the role and molecular mechanism of the ERα36-SLC7A5/LAT1 signaling axis in the malignant progression of cervical cancer and its sensitivity to boron neutron capture therapy (BNCT). - Source: PubMed
Publication date: 2026/08/18
Zhang LiliQuan RuiHuang HefaWang WeiZhang LuGu LongDai Zhongying - Cisplatin-based chemotherapy responses are highly heterogeneous across cancers, with the mechanisms governing drug sensitivity remaining incompletely understood. Using genome-wide CRISPR-Cas9 knockout screening, we systematically characterized regulators of cisplatin response and uncovered a counterintuitive finding: mTOR inhibition promotes cisplatin tolerance, contradicting the canonical view that PI3K-AKT-mTOR activation confers chemoresistance. Mechanistically, both mTOR suppression and cisplatin treatment converge to activate cytoprotective autophagy, which enhances cancer cell survival under therapeutic stress. The amino acid transporter SLC7A5 was identified and validated as a key integrator of the mTOR-autophagy axis that modulates cisplatin sensitivity. SLC7A5 expression positively correlates with cisplatin sensitivity across cancer cell lines, and its downregulation is associated with cisplatin resistance in multiple cancer types, supporting its potential as a mechanistically grounded predictive biomarker. Translationally, leucine supplementation sensitizes cancer cells to cisplatin in an SLC7A5-mTOR-autophagy-dependent manner. Collectively, our study defines a novel mTOR-autophagy adaptive loop governing cisplatin tolerance, positions SLC7A5 as a central regulatory node with both biomarker and therapeutic target value, and proposes leucine supplementation as a simple, translatable strategy to improve cisplatin efficacy in SLC7A5-expressing tumors. - Source: PubMed
Publication date: 2026/08/22
Rao PengchengZhang TairanLi JuWei WeidengXia XiaoqiangChen QianmingXu XiaopingFeng Xiaodong - Diabetic nephropathy (DN) is a major microvascular complication of diabetes. Hypoxia-inducible factor 1-alpha (HIF1A) and ferroptosis contribute to the progression of DN, but the circulating biomarkers associated with these pathways are still unknown. In this study, the whole-blood transcriptomic datasets in the Gene Expression Omnibus were combined with ferroptosis-related genes from the FerrDb database and published literature. The differentially expressed genes of HIF1A and of DN were intersected, and then the feature selection with Boruta and SVM-RFE was performed, followed by external validation, immune infiltration analysis, prediction of regulatory network, drug-target prediction, and RT-qPCR validation. We identified 773 HIF1A-related genes, 1445 DN-related genes, and 22 overlapping candidate genes. Using machine-learning analysis, nine core genes were identified, including SLC7A5 and SLC2A14, which consistently upregulated in both training and validation datasets and corroborated by RT-qPCR. Both genes were positively associated with activated natural killer cells and negatively associated with monocytes in estimated circulating immune-cell composition analysis. Regulatory-network and DrugBank analyses generated hypotheses regarding upstream miRNAs and potential compound interaction. These findings identify SLC7A5 and SLC2A14 as candidate circulating biomarkers related to HIF1A expression and ferroptosis-related gene signatures in DN. Further large-cohort and functional studies are required to confirm their diagnostic and mechanistic relevance. - Source: PubMed
Publication date: 2026/08/25
Li YufengBao JiaoSun RongMei WenjieLiu YonghongBai YanHu ChengxiangJiang Hongying - Colorectal cancer (CRC) is a leading cause of cancer-related death and is associated with high recurrence rates. Solute carrier family 7 member 5 (SLC7A5), a core transporter that facilitates the transmembrane movement of tryptophan, plays a role in various cancers. However, whether and how SLC7A5 promotes colorectal liver metastasis (CRLM) through tryptophan metabolism reprogramming and immune remodelling remain unexplored. - Source: PubMed
Luo YaohaoLi LeiLi ShanbaoWang XinshuaiHe ZepingSong FangbinQin JunZhang JinyanXu Junming - Vascular remodeling is a central pathological feature of cardiovascular diseases and is driven in part by vascular smooth muscle cell (VSMC) proliferation, migration, and phenotypic switching. The solute carrier family 7 member 5 (SLC7A5), a key amino acid transporter, has been implicated in cellular growth and metabolic regulation, but its role in vascular remodeling remains unclear. We investigated the contribution of SLC7A5 to VSMC activation and the underlying signaling mechanisms. - Source: PubMed
Publication date: 2026/07/14
Bai YuChen SixuanWang YueWu QimingYin Dechun